Business Wire

CA-BERKELEY-SKYDECK

2.8.2022 13:02:06 CEST | Business Wire | Press release

Share
Berkeley SkyDeck Introduces New Tracks Ahead of Open Applications for Next Cohort Class

Berkeley SkyDeck , the global hub for entrepreneurship and leading accelerator, today announced that applications are now open for its 15th cohort class, with a final deadline of August 31, 2022. Applications are available here . Batch 15 cohorts can take advantage of new tracks added in the last year, including the Aero-Astro Track, led by advisor Robin Riedel of McKinsey and Company, and the Blockchain/Crypto Track, led by advisor Linda Kreitzman. Berkeley SkyDeck’s Chip Track also named a new advisor, David Horsley of UC Davis. In addition, Berkeley SkyDeck will launch a CivTech Track in the coming year, in partnership with the Center for Security in Politics at UC Berkeley, with former Secretary of Homeland Security Janet Napolitano leading the track as a primary advisor. In addition to these new tracks, SkyDeck will continue to work with startups in industries that have always been an area of focus for venture investors, including consumer, enterprise software, biotech, greentech and more.

Berkeley SkyDeck accepts just over 1.5% of startups that apply and approximately 20 to 25 startups overall for each of its cohorts. Cohort companies receive $200,000 in funding, $750,000 worth of free and discounted resources, and access to SkyDeck’s unsurpassed network of UC Berkeley alumni, faculty, and advisors. Alumni of Berkeley SkyDeck have enjoyed great success in their respective industries, collectively raising more than $1.7 billion in funding. The recently launched Berkeley SkyDeck Europe is currently working with its first group of cohorts, who will present their own Demo Day on October 20, 2022.

“Our mission at Berkeley SkyDeck is to continue the tradition of excellence in entrepreneurship and innovation that makes UC Berkeley one of the top public universities in the world. Expanding our operations in Europe and opening additional tracks for our cohorts are just a couple examples of how we are striving to meet the needs of founders around the world,” said Caroline Winnett, Executive Director. “I am looking forward to seeing what these batch applicants have to offer – and how we can leverage the university’s vast resources to set them up for success.”

Berkeley SkyDeck’s newest tracks reflect trends in growth and investments. Last year, for example, aerospace startups raised $15.4 billion while US semiconductor and chip investment reached $2.6 billion in 2021 , nearly doubling in just three years. Civtech is also burgeoning, with the industry’s transaction volume rising to $14 billion total in 2021 .

“While Berkeley SkyDeck might be rooted here in Silicon Valley, our reach is global, and we’re excited to see how both homegrown and international startups tackle the issues in their industries across all of our tracks,” said Chon Tang, Founding Partner, Berkeley SkyDeck Fund. “As we evaluate, advise, and potentially invest, we are continually energized by these fresh ideas and new approaches. The SkyDeck Fund is ready and waiting to take these newest cohort companies to the next level.”

In March 2022, Berkeley SkyDeck recently announced the close of the $60 million SkyDeck Fund II, which continues to actively fund companies. The SkyDeck Fund has invested in 160 companies to date, representing a wide range of businesses and industries, from 30 countries around the world. Unlike other VC funds, the SkyDeck Fund shares half of its profits with UC Berkeley, helping to continue the university’s mission of delivering excellence in education.

Berkeley SkyDeck will conduct extensive research on applicants, and will hold interviews between September and October 2022. The six-month program will begin in November 2022, concluding at the end of April 2023. Berkeley SkyDeck will host the cohort’s Demo Day for investors on April 4, 2023.

About Berkeley SkyDeck

Berkeley SkyDeck is a leading accelerator and the global hub for entrepreneurship. As UC Berkeley’s largest and most prominent accelerator, SkyDeck combines hands-on mentorship with the vast resources of its research university. SkyDeck is the only accelerator of its kind that offers the value of a dedicated investment fund alongside the resources and network of a top university. To date, SkyDeck startups have raised more than $1.7 billion in aggregate. Participating startups have access to SkyDeck’s 420 advisors, 70 industry partners, and a network of more than 510,000 UC Berkeley alumni. For more information, see skydeck.berkeley.edu .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release

HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l

BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 202612.6.2026 12:00:00 CEST | Press release

Tacabrutideg (BGB-16673, BTK degrader) showed durable responses in heavily pretreated R/R CLL and BTK inhibitor–naïve patients, signaling potential for earlier lines of treatmentBRUKINSA plus sonrotoclax (ZS) delivered deep, durable responses and high uMRD rates across TN CLL and R/R MCL and CLL, reinforcing its potential as an all-oral, fixed-duration treatment BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from its foundational hematology franchise at the 2026 European Hematology Association (EHA) Congress in Stockholm. Updated results from tacabrutideg (BGB-16673), a potential best-in-class Bruton’s tyrosine kinase (BTK) degrader, demonstrated durable responses in pretreated relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), with early activity also seen in BTK inhibitor–naïve patients. These data are complemented by results from the all-oral combination of BRUKINSA® (zanubru

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye